ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Rebecca A Marsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.